Skip to main content

Table 3 Clinical course and treatment-related morbidity in patients with SSc not responding to autologous SCT

From: Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells

    Anti-double-   Steroid Karnofsky   Side effects
  Follow-up   stranded DNA:   dosage score   during
Patient* (months) ANA ELISA†‡ (iU/ml) Scl 70 (mg/day)†§ (%) Skin score immunoablation
5 13 5120 2.8 + Refused 60 19 SIRS: WHO grade II
Female/23 years/   steroids Isolated reduction of
1987   2560 None +   60 19    F VII to 3% (Q 21%)
6 6 5120 None + 20 70 30 SIRS: WHO grade II
Male/25 years/   
1995   2560 None + 20 70 30  
7 None 2560 None + 30 40 32 Fluid retention during
Female/45 years/      preparative regimen
1996   NE NE NE NE NE NE  
  1. *Characteristics: sex/age/year of diagnosis. Values above the arrow represent the admission values and those below the arrow represent the present status. ELISA cut-off was 118 iU/ml. §Doses corresponding to prednisolone equivalents. SIRS due to application of cyclophosphamide and ATG. ELISA, enzyme-linked immunosorbent assay; F VII, blood clotting factor VII; NE, not evaluable; Q, Quick's value (reciprocal value of prothrombin time of the test sample compared with that of normal plasma as percentage); SIRS, systemic inflammatory response syndrome; WHO, World Health Organization.